186 related articles for article (PubMed ID: 23718304)
1. Metastatic renal cell carcinoma: how to make the best sequencing decision after withdrawal for intolerance to a tyrosine kinase inhibitor.
Sabbatini R; Ortega C; Procopio G; Masini C; Galligioni E; Porta C
Future Oncol; 2013 Jun; 9(6):831-43. PubMed ID: 23718304
[TBL] [Abstract][Full Text] [Related]
2. Pazopanib for the treatment of metastatic renal cell carcinoma.
Pick AM; Nystrom KK
Clin Ther; 2012 Mar; 34(3):511-20. PubMed ID: 22341567
[TBL] [Abstract][Full Text] [Related]
3. Pazopanib: an orally administered multi-targeted tyrosine kinase inhibitor for locally advanced or metastatic renal cell carcinoma.
Koc G; Wang X; Luo Y
Can J Urol; 2011 Dec; 18(6):5991-7. PubMed ID: 22166325
[TBL] [Abstract][Full Text] [Related]
4. Sorafenib for the treatment of renal cancer.
Strumberg D
Expert Opin Pharmacother; 2012 Feb; 13(3):407-19. PubMed ID: 22263843
[TBL] [Abstract][Full Text] [Related]
5. Second-line systemic therapy for the treatment of metastatic renal cell cancer.
Kruck S; Bedke J; Kuczyk MA; Merseburger AS
Expert Rev Anticancer Ther; 2012 Jun; 12(6):777-85. PubMed ID: 22716494
[TBL] [Abstract][Full Text] [Related]
6. Pazopanib: an oral multitargeted tyrosine kinase inhibitor for use in renal cell carcinoma.
LaPlant KD; Louzon PD
Ann Pharmacother; 2010 Jun; 44(6):1054-60. PubMed ID: 20407031
[TBL] [Abstract][Full Text] [Related]
7. Thyroid dysfunction and tyrosine kinase inhibitors in renal cell carcinoma.
Bianchi L; Rossi L; Tomao F; Papa A; Zoratto F; Tomao S
Endocr Relat Cancer; 2013 Oct; 20(5):R233-45. PubMed ID: 23833016
[TBL] [Abstract][Full Text] [Related]
8. Novel tyrosine kinase inhibitors for renal cell carcinoma.
Dorff TB; Pal SK; Quinn DI
Expert Rev Clin Pharmacol; 2014 Jan; 7(1):67-73. PubMed ID: 24308791
[TBL] [Abstract][Full Text] [Related]
9. [First-line therapy in advanced renal cell carcinoma : A randomized phase II study to examine early switch of tyrosine kinase inhibitors to nivolumab compared to continued tyrosine kinase inhibitor therapy in patients with advanced or metastatic renal cell carcinoma and stable disease after three months of treatment (NIVOSWITCH)-AN 38/15 of the AUO].
Rexer H; Steiner T; Grünwald V
Urologe A; 2017 Apr; 56(4):509-511. PubMed ID: 28251253
[No Abstract] [Full Text] [Related]
10. New treatment approaches in renal cell carcinoma.
Facchini G; Perri F; Caraglia M; Pisano C; Striano S; Marra L; Fiore F; Aprea P; Pignata S; Iaffaioli RV
Anticancer Drugs; 2009 Nov; 20(10):893-900. PubMed ID: 19752718
[TBL] [Abstract][Full Text] [Related]
11. Sorafenib in renal cell carcinoma.
Arranz JÁ; Climent MÁ; González-Larriba JL; León L; Maroto JP
Crit Rev Oncol Hematol; 2011 Nov; 80(2):314-22. PubMed ID: 21419641
[TBL] [Abstract][Full Text] [Related]
12. The role of pharmacogenomics in metastatic renal cell carcinoma.
Castellano D; Virizuela JA; Cruz J; Sepulveda JM; Sáez MI; Paz-Ares L
Cancer Metastasis Rev; 2012 Sep; 31 Suppl 1():S29-32. PubMed ID: 22723081
[TBL] [Abstract][Full Text] [Related]
13. Update on novel agents in renal cell carcinoma.
Tamaskar I; Pili R
Expert Rev Anticancer Ther; 2009 Dec; 9(12):1817-27. PubMed ID: 19954293
[TBL] [Abstract][Full Text] [Related]
14. [Cytokine-based and targeted therapy of metastatic renal cell carcinoma--a current analysis].
Johannsen M; Ringsdorf M; Römer A; Loening SA; Roigas J
Aktuelle Urol; 2007 Jan; 38(1):38-45. PubMed ID: 17290328
[TBL] [Abstract][Full Text] [Related]
15. Sorafenib for the management of advanced renal cell carcinoma.
Escudier B
Expert Rev Anticancer Ther; 2011 Jun; 11(6):825-36. PubMed ID: 21707277
[TBL] [Abstract][Full Text] [Related]
16. Treatment of metastatic renal cell carcinoma.
Reeves DJ; Liu CY
Cancer Chemother Pharmacol; 2009 Jun; 64(1):11-25. PubMed ID: 19343348
[TBL] [Abstract][Full Text] [Related]
17. Present and future therapeutic options for locally advanced and metastatic renal cell carcinoma.
Sfoungaristos S; Giannitsas K; Perimenis P
Expert Opin Pharmacother; 2011 Mar; 12(4):533-47. PubMed ID: 21306289
[TBL] [Abstract][Full Text] [Related]
18. Targeted therapy and hand-foot skin reaction in advanced renal cell carcinoma.
Yang CH; Chuang CK; Hsieh JJ; Chang JW
Expert Opin Drug Saf; 2010 May; 9(3):459-70. PubMed ID: 20113155
[TBL] [Abstract][Full Text] [Related]
19. Optimizing further treatment choices in short- and long-term responders to first-line therapy for patients with advanced renal cell carcinoma.
Procopio G; Sabbatini R; Porta C; Verzoni E; Galligioni E; Ortega C
Expert Rev Anticancer Ther; 2012 Aug; 12(8):1089-96. PubMed ID: 23030227
[TBL] [Abstract][Full Text] [Related]
20. Safety and tolerability of pazopanib in the treatment of renal cell carcinoma.
Zivi A; Cerbone L; Recine F; Sternberg CN
Expert Opin Drug Saf; 2012 Sep; 11(5):851-9. PubMed ID: 22861374
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
